Liprolog

Insulin lispro, the active ingredient in Liprolog, is a rapid‑acting insulin analog presented as a sterile solution for subcutaneous, intramuscular, or intravenous use. It is used to manage blood glucose levels in patients with diabetes mellitus type 1 and type 2. GNH USA supplies Liprolog as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Liprolog, a rapid‑acting insulin analog, works within the insulin‑dependent glucose regulation pathway to lower blood sugar levels.

Diabetes mellitus type 1: provides mealtime glucose control to reduce hyperglycaemia. Diabetes mellitus type 2: assists in achieving post‑prandial glucose targets when diet, exercise, and oral agents are insufficient.

Common Side Effects: - Hypoglycaemia: low blood glucose episodes, especially if meals are missed. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Lipodystrophy: localized changes in subcutaneous fat with repeated injections.

Serious or Rare Side Effects: - Severe hypoglycaemia leading to seizures or loss of consciousness. - Anaphylactic reaction: hives, swelling, difficulty breathing. - Edema: abnormal fluid accumulation, particularly in the lower extremities.

When using Liprolog, consider the following safety measures. - Hypoglycaemia risk: monitor blood glucose frequently, especially before meals and physical activity. - Renal impairment: adjust dose as reduced clearance may increase insulin exposure. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Alcohol consumption: can mask hypoglycaemia symptoms, requiring closer glucose monitoring. - Concomitant beta‑blockers: may blunt typical hypoglycaemia warning signs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Liprolog may interact with several medicines; awareness helps maintain safe therapy.

Major Interactions (Avoid): - Sulfonylureas: combined use markedly increases hypoglycaemia risk. - Beta‑blockers: can conceal hypoglycaemia symptoms, complicating detection. - Intravenous glucose infusions: may require insulin dose reduction.

Moderate Interactions (Monitor Closely): - ACE inhibitors: may enhance insulin sensitivity, necessitating dose review. - Thiazide diuretics: can raise blood glucose, potentially requiring higher insulin doses. - Corticosteroids: may increase insulin requirements due to hyperglycaemic effect.